Regressão da nefropatia diabética experimental: ausência de efeito dose-resposta de um antagonista da angiotensina II / Regression of diabetic nephropathy : no dose-response effect of an angiotensin II antagonist
AUTOR(ES)
Flavio Teles de Farias Filho
DATA DE PUBLICAÇÃO
2007
RESUMO
Evidence of regression of glomerulosclerosis in diabetic nephropathy (DN) and other modalities of chronic kidney diseases has been provided in recent years. However, it remains unclear whether advanced lesions such as glomerular sinechiae can be reversed with pharmacological therapy, or whether this possibility exists only for relatively moderate damage such as mesangial expansion. Recently, the protective renal effect of AT-1 receptor blockers (ARBs) was shown to be dose-dependent in chronic nephropathies. To verify whether an ARB possess a dose-dependent renal effect and whether glomerular lesions can regress in DN, rats were made diabetic by streptozotocin and treated with a standard and an extremely high dose of losartan (L). L treatment reduced albuminuria and protected against glomerulosclerosis and glomerular inflammation, without an additional effect with high doses. There was regression of mesangial expansion with L. However, there was no regression in the frequency of glomerulosclerosis with sinechiae. These findings suggest no dose-dependent effect of L in this model of DN and that mesangial matrix removal is a feasible aim with ARBs in DN.
ASSUNTO(S)
diabetes mellitus ratos diabetes mellitus nefropatias diabéticas diabetic nephropathies losartan/therapeutic use rats losartan/uso terapéutico
